Abstract library

148 results for "Incremental benefit".
#1140 Incremental Benefit of Preoperative Endoscopic Ultrasound for the Detection of Pancreatic Neuroendocrine Tumors: A Meta-Analysis
Introduction: Current guidelines recommend computed tomography (CT) scan or magnetic resonance imaging as the initial imaging modalities for the work-up of suspected pancreatic neuroendocrine tumors (PNETs).
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: M.D, Ph.D. Apostolos Tsolakis
#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mónica Inês
Authors: Soares M, Inês M, Contente M, ...
#379 Laparoscopic Surgery of Pancreatic Endocrine Tumors: Is There a Benefit?
Introduction: Minimally invasive surgery is widely adopted for the treatment of surgical diseases, but results of laparoscopic procedures for pancreatic endocrine tumors (PET) are published in small series.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Markiyan Soloviy
Authors: Soloviy M, ...
#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial
Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Florence Marteau
#608 Is Octreotide Benefitial in Patients with Metastatic Gastroenteropancreatic (GEP) and Hepatobiliary Neuroendocrine Carcinoma (NEC)?
Introduction: Neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) and hepatobiliary (HB) tract are rare and a heterogenous group of malignancies. Octreotide showed the anti-tumor activity in well-differentiated metastatic midgut neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Seung Kim
Authors: Kim S, ...
Keywords: NEC, octreotide, GEP, HB
#486 Benefit of Octreotide LAR in Patients with Neuroendocrine Midgut Tumors Who Previously Progressed on Placebo Therapy: Two Cases From the PROMID Study
Introduction: In the phase IIIb PROMID study, patients with advanced low-/intermediate-grade midgut neuroendocrine tumors (NET) received Octreotide LAR (O; 30 mg IM q28d) or placebo (P). Median time to tumor progression (TTP) was increased 8.3 mo in patients receiving O v. P (HR=0.34; 95% CI, 0.20-0.59; P<0.0001).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Anja Rinke
Authors: Rinke A, ...
#1413 Everolimus (EVE) Treatment for Advanced G1-G2 Neuroendocrine Tumours (NETs) in the Community Setting: Clinical Benefit Irrespective of Previous Therapies
Introduction: Randomized studies have shown EVE has antitumour activity in advanced G1-G2 NETs. However, data outside regulatory trials are limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD PhD Ana Custodio
#1607 Perioperative Carcinoid Crisis During Surgery- Who Benefits from Octreotide?
Introduction: Carcinoid crisis, as an entity is poorly defined, but can be seen in patients with small bowel NET after open bowel surgery or tumour unrelated procedures as cardiovascular instability (CI)
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Khalil Elgendy
Authors: Elgendy K, Johnson S, French J, White S, ...
#2081 Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition
Introduction: Somatostatin analogues (SSA) such as Octreotide and Lanreotide have demonstrated a significant benefit in Neuroendocrine Tumors, particularly in the well/moderately differentiated types. Nevertheless, there are still several aspects of SSA treatments that remain unsolved, such as drug exposition in patients and schedule optimization.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Oriol Casanovas
#2227 Screening Benefits in MEN1-Associated Pituitary Adenomas
Introduction: MEN1 is an autosomal-dominant syndrome characterized by tumors of the parathyroid glands (95%), endocrine pancreatic-gastroenteric tract (40%), and pituitary gland (30%).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: md Sabrina Chiloiro